Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1642-1649
doi: 10.1161/hq1001.096722
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morton, R. E.
Right arrow Articles by Quintão, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morton, R. E.
Right arrow Articles by Quintão, E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
Related Collections
Right arrow Biochemistry and metabolism
Right arrow Risk Factors
Right arrow Gene regulation
Right arrow Lipid and lipoprotein metabolism
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1642.)
© 2001 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Markedly Elevated Lipid Transfer Inhibitor Protein in Hypercholesterolemic Subjects Is Mitigated by Plasma Triglyceride Levels

Richard E. Morton; Valéria Nunes; Lahoucine Izem; Eder Quintão

From the Department of Cell Biology (R.E.M., L.I.), Lerner Institute, Cleveland Clinic Foundation, Cleveland, Ohio, and the Lipids Laboratory (V.N., E.Q.), University of São Paulo Medical School, São Paulo, Brazil.

Correspondence to Richard E. Morton, PhD, Cell Biology, NC10, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. E-mail mortonr{at}ccf.org

Abstract— Lipid transfer inhibitor protein (LTIP, apolipoprotein F) regulates the interaction of cholesteryl ester transfer protein (CETP) with lipoproteins and is postulated to enhance the ability of CETP to stimulate reverse cholesterol transport. The factors that regulate LTIP levels and control its biosynthesis are unknown. Here, we demonstrate that plasma LTIP is dramatically increased (3-fold) in hypercholesterolemic subjects with normal to mildly elevated plasma triglyceride (TG) levels compared with control subjects. LTIP in these subjects is not correlated with the extent of hypercholesterolemia or with low density lipoprotein (LDL), high density lipoprotein, or CETP levels. However, unlike CETP, LTIP levels correlate negatively with plasma TG levels. This association does not appear to reflect decreased LTIP synthesis, inasmuch as conditions that stimulate TG synthesis and secretion (200 µmol/L oleate) do not reduce LTIP secretion by SW872 or Caco-2 cells. In contrast, native or acetyl LDL stimulates LTIP secretion 2-fold. Importantly, although plasma LTIP typically resides on LDL, up to 25% of LTIP is bound to very low density lipoprotein when this lipoprotein is enriched in cholesteryl esters, as occurs in hypercholesterolemia. In summary, LTIP levels are markedly elevated by hypercholesterolemia; however, plasma TG levels attenuate this response. We hypothesize that this arises from an increased association of LTIP with very low density lipoprotein, leading to a more rapid clearance of the inhibitor from circulation.


Key Words: hypercholesterolemia • cholesteryl ester transfer protein • lipid transfer inhibitor protein • triglycerides • lipoprotein metabolism




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
L. Izem and R. E. Morton
Molecular cloning of hamster lipid transfer inhibitor protein (apolipoprotein F) and regulation of its expression by hyperlipidemia
J. Lipid Res., April 1, 2009; 50(4): 676 - 684.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
W. R. Lagor, R. J. Brown, S.-A. Toh, J. S. Millar, I. V. Fuki, M. de la Llera-Moya, T. Yuen, G. Rothblat, J. T. Billheimer, and D. J. Rader
Overexpression of Apolipoprotein F Reduces HDL Cholesterol Levels In Vivo
Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 40 - 46.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
Y. He, D. J. Greene, M. Kinter, and R. E. Morton
Control of cholesteryl ester transfer protein activity by sequestration of lipid transfer inhibitor protein in an inactive complex
J. Lipid Res., July 1, 2008; 49(7): 1529 - 1537.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
R. E. Morton, H. M. Gnizak, D. J. Greene, K.-H. Cho, and V. M. Paromov
Lipid transfer inhibitor protein (apolipoprotein F) concentration in normolipidemic and hyperlipidemic subjects
J. Lipid Res., January 1, 2008; 49(1): 127 - 135.
[Abstract] [Full Text] [PDF]